OptiBiotix continues LPLDL® growth with latest CholBiome® distribution deal

OptiBiotix Health Plc. (OptiBiotix) a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has entered a three-year agreement with a leading pharmaceutical distribution company in Bulgaria.

The deal covers the distribution and commercialisation of OptiBiotix’s CholBiome® products, which contain its cholesterol and blood pressure reducing probiotic strain LPLDL®. The deal is a first in Europe for the CholBiome® range following its recent launch online in the UK.

Under the three-year agreement, the Bulgarian pharmaceutical company will exclusively distribute CholBiome® products in return for local product registration, with three-year sales targets enabling exclusivity retention.

The agreement will extend the sales of CholBiome® products into a country with a high risk of cardiovascular conditions, as well as presenting opportunities to other partners to expand into additional territories outside of Bulgaria in the future. The agreement complements existing sales channels for LPLDL®, increasing value generation for the probiotic division of OptiBiotix.

Per Rehné, OptiBiotix Commercial Director, said: “We are very pleased to announce this agreement with a company that has access to a large majority of pharmacies in the country.

“It demonstrates significant progress in increasing the sales channels of LPLDL® and will add additional value to this next-generation probiotic. We chose the company for its significant market access and solid track record in delivering impressive product sales. We hope tosee other significant territories begin to recognise the value of this unique ingredient in the near future.”

CholBiome® products harness the power of OptiBiotix’s patented probiotic Lactobacillus plantarum, LPLDL®, to offer a scientifically-backed, natural solution for people wishing to pro-actively reduce and manage cholesterol, reduce blood pressure and promote heart wellness.

To protect its commercial interests, the company requires its identity and the terms of the agreement to remain confidential. Therefore, no further details can be disclosed. Further announcements will be made in due course.